Stock Analiz

Nurix Therapeutics, Inc. (NRIX) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Nurix Therapeutics’s revenue went from $31M in fiscal 2019 to $84M in fiscal 2025, growth of about 18.0% a year.

Net income in fiscal 2025 was -$264M, a net margin of -314.9%; the best year in this period was 2019 with -$22M.

Over the twelve months to August 31, 2026, revenue was $702M and net income $295M.

Free cash flow was -$263M in fiscal 2025 and positive in 0 of the 7 years shown.

The diluted share count rose 2532% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2019: $31M20192020: $18M20202021: $30M20212022: $39M20222023: $77M20232024: $55M20242025: $84M2025$84M
Net income
2019: -$22M20192020: -$43M20202021: -$117M20212022: -$180M20222023: -$144M20232024: -$194M20242025: -$264M2025-$264M
Free cash flow
2019: -$1M20192020: -$5M20202021: -$90M20212022: -$172M20222023: -$90M20232024: -$182M20242025: -$263M2025-$263M
EPS (diluted)
2019: $-6.5920192020: $-2.7620202021: $-2.7320212022: $-3.7120222023: $-2.6520232024: $-2.8820242025: $-3.052025$-3.05

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$702M$84M$55M$77M$39M$30M$18M$31M
Gross profit————————
Operating income$290M-$286M-$213M-$155M-$184M-$118M-$65M-$22M
Net income$295M-$264M-$194M-$144M-$180M-$117M-$43M-$22M
EPS (diluted)$2.43$-3.05$-2.88$-2.65$-3.71$-2.73$-2.76$-6.59
R&D$334M$317M$222M$189M$184M$116M$66M$45M
Revenue growth—+53.9%−29.1%+99.3%+29.8%+67.0%−42.7%—

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow$379M-$249M-$173M-$81M-$160M-$84M-$80000$601000
Capital spending-$10M-$14M-$9M-$8M-$12M-$6M-$5M-$2M
Free cash flow$370M-$263M-$182M-$90M-$172M-$90M-$5M-$1M
Dividends paid—$0$0$0$0$0$0$0
Buybacks————————
Stock-based pay$41M$38M$34M$34M$28M$16M$4M$510000

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$247M$110M$55M$309M$296M$281M$38M
Debt—$56M$28M$31M$12M$13M$0$0
Equity—$539M$527M$200M$304M$342M$290M-$58M
Total assets—$688M$669M$356M$417M$477M$396M$44M
Shares (diluted)116M87M67M54M49M43M16M3M

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin————————
Operating margin41.3%-340.2%-390.5%-201.4%-476.0%-396.3%-364.7%-71.5%
Net margin42.0%-314.9%-354.9%-187.0%-466.9%-393.9%-242.7%-69.7%
FCF margin52.7%-313.7%-333.4%-116.6%-445.4%-302.6%-26.0%-3.4%
ROIC—-38.0%-30.3%-67.1%-58.2%-26.2%-15.2%—
ROE—-49.1%-36.7%-71.8%-59.4%-34.2%-14.9%37.6%

Frequently asked questions

What is Nurix Therapeutics’s annual revenue?

$84M in fiscal 2025 and $702M over the twelve months to August 31, 2026.

How much profit does Nurix Therapeutics make?

Net income was -$264M in fiscal 2025 (net margin -314.9%).

Is Nurix Therapeutics’s revenue growing?

Yes: revenue rose 54.0% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.